Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06961110

Evaluation of Molecular Hydrogen Supplementation to Enhance the Efficacy of Weight Loss Retreat in Overweight and Obese Adolescents

This randomized controlled trial evaluates whether molecular hydrogen supplementation enhances the effectiveness of a 4-week weight loss retreat in overweight and obese adolescents. Outcome measures include: body composition, physical status, blood samples (insulin sensitivity, lipid profiles, markers of oxidative stress and inflammation) and autonomic nervous system function.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

11 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Palacky University, Faculty of Physical Culture

Olomouc, Czech Republic, 77111, Czechia

About this study

The aim of this randomized, double-blind, parallel-group, placebo-controlled trial is to evaluate whether molecular hydrogen supplementation enhances the effectiveness of weight loss retreat for overweight and obese adolescents. Weight loss retreat is indicated for participants based on diagnosis and recommendation of a pediatrician. During the 4-week retreat, participants follow a prescribed standardized intervention consisting of reduction diet and physical activity. The total planned number of participants is 60. Participants are randomly divided into two balanced groups, with one group receiving molecular hydrogen in the form of hydrogen-rich water and the other receiving a placebo water. The daily amount of water given (hydrogen-rich or placebo) is 1.5 L. Hydrogen-rich water is packaged in specially designed aluminum containers to minimize hydrogen leakage and ensure long-term stability with a dissolved hydrogen concentration of 1.2-1.6 ppm. Participants are unable to distinguish hydrogen-rich water from the placebo because molecular hydrogen is colorless, odorless, and tasteless. Participants monitor their physical activity, sleep, and sedentary behavior one week before to retreat and undergo baseline diagnostics (including blood sampling), three weekly interim diagnostics during retreat, and final diagnostics (including blood sampling) after four weeks. If participants are available, two follow-up diagnostics are conducted six weeks and six months after the retreat and include seven-day monitoring of physical activity, sleep, and sedentary behavior. Statistical analysis is performed at a significance level of α = 0.05 and the data is evaluated using analysis of variance. In cases of non-normality, data transformations or non-parametric alternatives are used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index indicating overweight or obesity, as determined according to the World Health Organization's international percentile charts for children aged 5-19 years.
  • Presence of a regular menstrual cycle in female participants.
  • Signed informed consent from the legal representative.

Exclusion criteria

  • High blood pressure.
  • Dyslipoproteinemia.
  • Cardio-respiratory disorders.
  • Musculoskeletal disorders.
  • Use of any medications regulating heart rhythm or the neurovegetative and hormonal system.

Treatment and study plan

Hydrogen-rich water

Dietary Supplement

Hydrogen-rich water with molecular hydrogen concentration 1.2-1.6 ppm. No added sugar or preservatives.

Other names: H2 Premium Hydrogen Water, H2 World Health & Beauty Company, Ostrava, Czech Republic

Placebo

Dietary Supplement

Drinking water with molecular hydrogen concentration 0.0 ppm. No added sugar or preservatives.

Other names: H2 Premium Hydrogen Water (Placebo), H2 World Health & Beauty Company, Ostrava, Czech Republic

Primary outcomes

  1. Body mass index

    Time frame: Baseline and 4 weeks

    Body mass index is calculated as the ratio of body mass (kg) to the square of body height (m2). Body mass is measured using a digital scale to the nearest 0.1 kg and body height is measured using a stadiometer to the nearest 1 cm.

  2. Six-minute walk test

    Time frame: Baseline and 4 weeks

    Six-minute walk test is measured by recording the total distance the participant is able to walk on a flat surface within six minutes. The participant is instructed to walk at his/her own pace in order to walk as far as possible in the given time.

Secondary outcomes

  1. Body fat

    Time frame: Baseline and 4 weeks

    Body fat is measured using bioelectrical impedance analysis (InBody 270, InBody, Seoul, South Korea).

  2. 30-second sit-to-stand test

    Time frame: Baseline and 4 weeks

    30-second sit-to-stand test is measured by counting the number of repetitions in which the participant rises from sitting in a chair and sits back down within 30 seconds.

  3. Maximal isometric grip force

    Time frame: Baseline and 4 weeks

    Maximal isometric grip force is measured using a hand dynamometer. The test is performed seated, with the elbow flexed at 90 degrees, and wrist in a neutral position.

  4. Maximal wall sit

    Time frame: Baseline and 4 weeks

    Maximal wall sit is measured by recording the maximum duration for which the participant can maintain a static isometric squat position against a wall.

  5. Resting blood lactate

    Time frame: Baseline and 4 weeks

    The level of resting blood lactate is measured using the Lactate Scout+ (EKF Diagnostics, Cardiff, United Kingdom). Capillary blood is collected in a fasting state from the fingertip using a sterile disposable lancet. Immediately after collection, the blood sample is applied to the test strip of the lactate meter and analyzed in real time.

  6. Homeostatic model assessment of insulin resistance

    Time frame: Baseline and 4 weeks

    Homeostatic model assessment of insulin resistance is calculated based on fasting glucose and fasting insulin levels measured from blood samples obtained via venipuncture by a healthcare specialist. Plasma glucose is separated by centrifugation and analyzed using an enzymatic colorimetric method. Serum insulin is separated by centrifugation and analyzed using a chemiluminescent immunoassay.

  7. Total cholesterol

    Time frame: Baseline and 4 weeks

    The level of total cholesterol is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method.

  8. Low-density lipoprotein

    Time frame: Baseline and 4 weeks

    The level of low-density lipoprotein is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method.

  9. High-density lipoprotein

    Time frame: Baseline and 4 weeks

    The level of high-density lipoprotein is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method.

  10. Triglycerides

    Time frame: Baseline and 4 weeks

    The level of triglycerides is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation and analyzed using an enzymatic colorimetric method.

  11. Cortisol

    Time frame: Baseline and 4 weeks

    The level of cortisol is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The serum is separated by centrifugation and analyzed using a chemiluminescent immunoassay.

  12. Fibroblast growth factor 21

    Time frame: Baseline and 4 weeks

    The level of fibroblast growth factor 21 is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis.

  13. Total antioxidant capacity

    Time frame: Baseline and 4 weeks

    The level of total antioxidant capacity is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until analysis using the TROLOX equivalent antioxidant capacity assay.

  14. Malondialdehydes

    Time frame: Baseline and 4 weeks

    The level of malondialdehydes is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis.

  15. Protein carbonyls

    Time frame: Baseline and 4 weeks

    The level of protein carbonyls is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis.

  16. Interleukin-6

    Time frame: Baseline and 4 weeks

    The level of interleukin-6 is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis.

  17. Tumor necrosis factor alpha

    Time frame: Baseline and 4 weeks

    The level of tumor necrosis factor alpha is measured from a fasting blood sample obtained via venipuncture by a healthcare specialist. The plasma is separated by centrifugation, divided into cryotubes, and stored at -80°C until ELISA analysis.

Other outcomes

  1. Waist circumference

    Time frame: Baseline and 4 weeks

    Waist circumference is be measured at the narrowest part of the torso, above the iliac crest and below the lowest rib, using a non-elastic tape.

  2. Blood pressure

    Time frame: Baseline and 4 weeks

    Blood pressure is measured using a mercury sphygmomanometer.

  3. Hydration Status

    Time frame: Baseline and 4 weeks

    Hydration status is assessed by measuring the urine specific gravity of morning urine sample using a refractometer (SUR-NE, ATAGO, Tokyo, Japan).

  4. Subjective evaluation of lower limb soreness

    Time frame: Baseline and 4 weeks

    Subjective evaluation of lower limb soreness is measured using a Visual Analog Scale before and after a wall-sit exercise, with the duration individually adjusted to 65% of each participant's maximum hold time. The Visual Analog Scale consists of a 100 mm line ranging from 0 mm (no soreness) to 100 mm (unbearable soreness).

  5. Heart rate variability

    Time frame: Baseline and 4 weeks

    Heart rate variability is measured using an ECG device (DiANS PF8, DIMEA Group, Olomouc, Czech Republic). ECG recording is performed during the orthoclinostatic maneuver in a calm room without acoustic and visual disturbances.

  6. Physical Activity Level

    Time frame: Baseline and 4 weeks

    The level of physical activity is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer provides detailed data on the intensity, frequency, and duration of physical activity.

  7. Sedentary Behavior

    Time frame: Baseline and 4 weeks

    Sedentary behavior is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer identifies frequency and duration of sedentary bouts.

  8. Sleep duration

    Time frame: Baseline and 4 weeks

    Sleep duration and quality is assessed using a wrist-worn tri-axial accelerometer (AX3, Axivity, Newcastle, United Kingdom). This accelerometer detects sleep patterns and provides total sleep time, sleep efficiency, and the timing of sleep periods.

Sponsors and collaborators

Lead sponsor

Palacky University

Other

Registry information

Official study title

Evaluation of Molecular Hydrogen Supplementation to Enhance the Efficacy of Weight Loss Retreat in Overweight and Obese Adolescents. A Randomized, Double-blind, Parallel-group, Placebo-controlled Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 7, 2025
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.